1-10 of 10
Nicolas Martin
Close
Sort by
Journal Articles

Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A 2 to promote inflammation

Luc H. Boudreau, Anne-Claire Duchez, Nathalie Cloutier, Denis Soulet, Nicolas Martin, James Bollinger, Alexandre Paré, Matthieu Rousseau, Gajendra S. Naika, Tania Lévesque, Cynthia Laflamme, Geneviève Marcoux, Gérard Lambeau, Richard W. Farndale, Marc Pouliot, Hind Hamzeh-Cognasse, Fabrice Cognasse, Olivier Garraud, Peter A. Nigrovic, Helga Guderley, Steve Lacroix, Louis Thibault, John W. Semple, Michael H. Gelb, Eric Boilard
Journal: Blood
Blood (2014) 124 (14): 2173–2183.
https://doi.org/10.1182/blood-2014-05-573543
Published: 2014
Includes: Multimedia, Supplemental data
Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP
Journal: Blood
Blood (2013) 122 (21): 1016.
https://doi.org/10.1182/blood.V122.21.1016.1016
Published: 2013
Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD
Journal: Blood
Blood (2012) 120 (21): 1028.
https://doi.org/10.1182/blood.V120.21.1028.1028
Published: 2012
Journal Articles

Interim Safety and Effectiveness Results From a 5-Year Observational Study of Deferasirox in Pediatric Patients Aged 2–<6 Years At Enrollment.

Elliott Vichinsky, MD, Amal El-Beshlawy, MD, Azzam Alzoebie, MD, Francoise Bernaudin, MD, Suzanne Koussa, MD, Thirachit Chotsampancharoen, MD, Ali El-Ali, MD, Caroline Arrowsmith, Nicolas Martin, MS, Mohsen El-Alfy, MD
Journal: Blood
Blood (2012) 120 (21): 2125.
https://doi.org/10.1182/blood.V120.21.2125.2125
Published: 2012
Journal Articles

Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.

John B Porter, MD, Mohsen Elalfy, MD, Vip Viprakasit, MD, DPhil, Stephane Giraudier, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD
Journal: Blood
Blood (2012) 120 (21): 2126.
https://doi.org/10.1182/blood.V120.21.2126.2126
Published: 2012
Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD
Journal: Blood
Blood (2012) 120 (21): 5182.
https://doi.org/10.1182/blood.V120.21.5182.5182
Published: 2012
Journal Articles

A Ruxolitinib Individual Supply Program for Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Giovanni Barosi, MD, Francisco Cervantes, MD, PhD, Dina Ben-Yehuda, MD, Panagiotis Panagiotidis, Jose Ricardo Perez, MD, Nancy D. Orlando-Harper, Nicolas Martin, MS, Wolfgang Willenbacher, MD, Emilio Ojeda, MD, PhD, Heinz Gisslinger, MD, Laurent Knoops, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 5170.
https://doi.org/10.1182/blood.V118.21.5170.5170
Published: 2011
Journal Articles

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Ruben A. Mesa, MD, Srdan Verstovsek, MD, PhD, Francisco Cervantes, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Nicolas Martin, MS, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Claire N. Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2011) 118 (21): 1753.
https://doi.org/10.1182/blood.V118.21.1753.1753
Published: 2011
Journal Articles

Distinct Functions of Stat5A and Stat5B in Chronic Myeloid Leukemia (CML): Stat5B Is Implicated in Survival and Self-Renewal and Stat5A in Imatinib Resistance.

Imen Najjar, PhD, Adrien Grimont, Nicolas Martin, Severine Martin-Lanneree, Marie Laure Bonnet, Francois Guilhot, Jean-Claude Chomel, Evelyne Lauret, Ali G. Turhan, MD, PhD, Isabelle Dusanter-Fourt, PhD
Journal: Blood
Blood (2010) 116 (21): 1214.
https://doi.org/10.1182/blood.V116.21.1214.1214
Published: 2010
Journal Articles

Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease

Clinical Trials & Observations
Achille Aouba, Sophie Georgin-Lavialle, Christian Pagnoux, Nicolas Martin Silva, Amédée Renand, Françoise Galateau-Salle, Sophie Le Toquin, Henri Bensadoun, Frederique Larousserie, Stéphane Silvera, Nicole Provost, Sophie Candon, Raphaèle Seror, Mathilde de Menthon, Olivier Hermine, Loïc Guillevin, Boris Bienvenu
Journal: Blood
Blood (2010) 116 (20): 4070–4076.
https://doi.org/10.1182/blood-2010-04-279240
Published: 2010